Biomarkers may help predict progression of Barrett's esophagus to esophageal adenocarcinoma

A series of microRNA expression signatures that may help to define progression of the precancerous condition Barrett's esophagus into esophageal adenocarcinoma was reported recently in Cancer Prevention Research, a journal of the American Association for Cancer Research.

"Once a representing only 5 percent of all esophageal cancers in the United States, esophageal adenocarcinoma is the cancer with the fastest-rising incidence—six-fold increase in the past three decades—and currently comprises more than 80 percent of all new cases in this country," said Xifeng Wu, M.D., chair of the Department of Epidemiology, Division of Cancer Prevention and Population Sciences at The University of Texas MD Anderson Cancer Center, in Houston. "To reduce the mortality of esophageal adenocarcinoma, the best hope in the near term is to detect it at its early stage, or even better, to prevent the progression of esophageal adenocarcinoma from its premalignant lesion, which is called Barrett's esophagus."

Wu and colleagues evaluated microRNAs, which are a class of small in cells capable of regulating a large number of genes. Research has shown that aberrant expression of microRNAs is involved in .

The researchers compared hundreds of microRNAs in normal esophageal epithelia and in Barrett's esophagus and esophageal adenocarcinoma tissues of different histological grades with distinct progression risks. They identified a number of differentially expressed microRNAs at each histological stage.

"The expression of microRNAs in Barrett's esophagus and esophageal adenocarcinoma tissues was remarkably similar, indicating that the microRNA aberrations were very early events in the development of Barrett's esophagus," Wu said. "These aberrations in microRNA expression may drive other late events that ultimately lead to carcinoma formation."

The researchers also identified a small number of microRNAs that were significantly different between Barrett's esophagus and esophageal adenocarcinoma. Specifically, downregulation of the microRNA miR-375 and upregulation of five microRNAs of the miR-17-92 and homologue family seemed to differentiate Barrett's esophagus and esophageal adenocarcinoma.

"Therefore, those patients with Barrett's esophagus with low levels of miR-375 and/or high levels of the other five microRNAs we found to be upregulated in esophageal adenocarcinoma are at increased risk for malignant progression and should be under intensive surveillance, screening and treatment of their Barrett's esophagus," Wu said.

"Defining the protein-coding genes targeted by the differentially expressed microRNAs we identified may provide significant biological insights into the development of ," she added. "Moreover, these genes may themselves become promising biomarkers to predict Barrett's esophagus progression as well as potential preventive and therapeutic targets."

add to favorites email to friend print save as pdf

Related Stories

Aspirin protects against Barrett's esophagus

Jul 23, 2012

Aspirin use appears to reduce the risk of Barrett's esophagus (BE), the largest known risk factor for esophageal cancer, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journa ...

Recommended for you

Researcher to cancer: 'Resistance will be futile'

4 hours ago

Turning the tables, Katherine Borden at the University of Montreal's Institute for Research in Immunology and Cancer (IRIC) has evoked Star Trek's Borg in her fight against the disease. "Cancer cells rapidly ...

How does prostate cancer form?

6 hours ago

Prostate cancer affects more than 23,000 men this year in the USA however the individual genes that initiate prostate cancer formation are poorly understood. Finding an enzyme that regulates this process ...

Low risk of malignancy for small complex adnexal masses

13 hours ago

(HealthDay)—For older women with small complex adnexal masses, the overall risk of malignancy is low, according to a study published in the December issue of the American Journal of Obstetrics & Gynecology.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.